Hjem › Tripelnegativ brystkreft › Texas › Austin
Kliniske studier for Tripelnegativ brystkreft i Austin, TX
13 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Austin (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- NEXT Austin, Austin
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- New Experimental Therapeutics - NEXT Oncology, Austin
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
- NEXT Oncology, Austin
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- NEXT Oncology Austin, Austin
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Texas Oncology, Austin
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruttererFase 2/3
- Texas Oncology - Central/South Texas, Austin
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- Texas Oncology - Central / South Texas, Austin
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruttererFase 1
- NEXT Oncology Austin /ID# 243005, Austin
Study of XB010 in Subjects With Solid Tumors
RekruttererFase 1
- NEXT Austin, Austin
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RekruttererFase 1
- NEXT Texas LLC - Austin, Austin
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
RekruttererFase 1
- NEXT Oncology, Austin, TX 78758
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RekruttererFase 1
- Dren Investigational Site, Austin
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RekruttererFase 2
- Texas Oncology PA (Austin), Austin
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Austin
- Ikke-småcellet lungekreft30 studier
- Kreft (alle typer)20 studier
- Fedme20 studier
- Kolorektal kreft19 studier
- Metastatisk kreft19 studier
- Overvekt18 studier
- Hjertesvikt18 studier
- Brystkreft18 studier
- Eggstokkreft17 studier
- Endometriekreft15 studier
- Prostatakreft15 studier
- Depresjon14 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.